[ad_1]
LONDON–(BUSINESS WIRE)–Nov 16, 2022–
LabGenius, a pioneer in the usage of machine studying (ML) for antibody-based drug discovery, right now introduced the appointment of Leonard Wossnig Ph.D. as Chief Know-how Officer (CTO). On this position, Leonard will lead a group of Knowledge Scientists, Software program Engineers, and Automation Consultants to additional improve LabGenius’ data-driven platform capabilities.
This press launch options multimedia. View the complete launch right here: https://www.businesswire.com/news/home/20221115005063/en/
Dr. Leonard Wossnig, LabGenius CTO (Picture: Enterprise Wire)
“Leonard is a superb addition to our group,” says LabGenius’ CEO and Founder, Dr. James Area. “His confirmed observe file of implementing cutting-edge machine studying options for drug discovery programmes will supercharge our capability to ship throughout a number of discovery initiatives.”
In 2018, Leonard co-founded Rahko, a number one quantum machine studying firm whose know-how platform mixed computational chemistry, machine studying and quantum computing to drive a greater understanding of drug behaviour. Throughout his time as CEO, Leonard directed Rahko’s business and scientific technique, which aimed to take away bottlenecks in drug discovery by making use of quantum machine studying fashions to the identification and optimisation of potential drug candidates. Earlier this yr, Rahko was acquired by Odyssey Therapeutics, the place, as VP of AI, Leonard led a group of machine studying consultants to develop a computational platform for generative drug design within the areas of most cancers and irritation.
Commenting on his appointment, Leonard stated: “The ML-driven antibody-based platform that the group at LabGenius has constructed presents a possibility to revolutionise right now’s strategy to drug discovery. By means of the event of bespoke automated pipelines, the group is ready to generate high-quality information at scale — this can be a essential precursor to the efficient use of machine studying. With these strong foundations in place, I’m excited to use my experiences to assist unlock the huge potential that computational strategies should speed up the invention of higher medicines.”
Dr. Edwin Moses, LabGenius’ Chairman commented that “Leonard’s appointment reinforces LabGenius’ dedication to technical excellence. His experience in generative molecule design, paired with LabGenius’ cutting-edge drug discovery platform, is a wonderful mixture, which can additional speed up the corporate’s capability to find uniquely highly effective protein-based therapeutics.”
– finish –
About LabGenius
Headquartered in London, LabGenius is a number one machine learning-driven protein engineering firm. The corporate’s core know-how platform, EVA™, allows the fast discovery of novel therapeutic antibodies. LabGenius’ extremely multidisciplinary group brings collectively the perfect minds from the fields of laptop science, robotic automation and artificial biology.
For extra data, please go to www.labgeni.us, or join on Twitter, LinkedIn and Medium.
View supply model on businesswire.com:https://www.businesswire.com/news/home/20221115005063/en/
CONTACT: For media enquiries, please contact Lucy Shaw atpress@labgeni.us
For enterprise growth, please contact James Area atpartnerships@labgeni.us
KEYWORD: EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA
INDUSTRY KEYWORD: DATA MANAGEMENT MANUFACTURING TECHNOLOGY ROBOTICS PHARMACEUTICAL PROFESSIONAL SERVICES VENTURE CAPITAL OTHER MANUFACTURING OTHER TECHNOLOGY BIOTECHNOLOGY SCIENCE SOFTWARE OTHER SCIENCE RESEARCH HEALTH ENGINEERING
SOURCE: LabGenius
Copyright Enterprise Wire 2022.
PUB: 11/16/2022 03:00 AM/DISC: 11/16/2022 03:02 AM
Copyright Enterprise Wire 2022.
[ad_2]
Source link
